Art

J-GLOBAL ID：201202202462797000   Reference number：12A1121945

Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update

肝細胞癌治療用の新規抗癌剤使用に関するガイドライン2010年最新版

Author (40)： KANEKO Shuichi (Novel Anticancer Agent Guideline Drafting Committee) ,  KANEKO Shuichi (Study Group on New Liver Cancer Therapies) ,  KANEKO Shuichi (Kanazawa Univ., Kanazawa) ,  FURUSE Junji (Novel Anticancer Agent Guideline Drafting Committee) ,  FURUSE Junji (Study Group on New Liver Cancer Therapies) ,  FURUSE Junji (Kyorin Univ. School of Medicine, Mitaka) ,  KUDO Masatoshi (Novel Anticancer Agent Guideline Drafting Committee) ,  KUDO Masatoshi (Study Group on New Liver Cancer Therapies) ,  KUDO Masatoshi (Kinki Univ., Higashiosaka) ,  IKEDA Kenji (Novel Anticancer Agent Guideline Drafting Committee) ,  IKEDA Kenji (Study Group on New Liver Cancer Therapies) ,  IKEDA Kenji (Toranomon Hospital, Tokyo) ,  HONDA Masao (Study Group on New Liver Cancer Therapies) ,  HONDA Masao (Kinki Univ., Higashiosaka) ,  NAKAMOTO Yasunari (Study Group on New Liver Cancer Therapies) ,  NAKAMOTO Yasunari (Fukui Univ., Fukui) ,  ONCHI Morikazu (Study Group on New Liver Cancer Therapies) ,  ONCHI Morikazu (Ehime Univ., Matsuyama) ,  SHIOTA Goshi (Study Group on New Liver Cancer Therapies) ,  SHIOTA Goshi (Tottori Univ. Graduate School of Medicine, Tottori) ,  YOKOSUKA Osamu (Study Group on New Liver Cancer Therapies) ,  YOKOSUKA Osamu (Chiba Univ., Chiba, JPN) ,  SAKAIDA Isao (Study Group on New Liver Cancer Therapies) ,  SAKAIDA Isao (Yamaguchi Univ. Graduate School of Medicine, Yamaguchi) ,  TAKEHARA Tetsuo (Study Group on New Liver Cancer Therapies) ,  TAKEHARA Tetsuo (Osaka Univ. Graduate School of Medicine, Osaka) ,  UENO Yoshiyuki (Study Group on New Liver Cancer Therapies) ,  UENO Yoshiyuki (Tohoku Univ. Graduate School of Medicine, Sendai) ,  HIROISHI Kazumasa (Study Group on New Liver Cancer Therapies) ,  HIROISHI Kazumasa (Showa Univ. School of Medicine, Tokyo) ,  NISHIGUCHI Shuhei (Study Group on New Liver Cancer Therapies) ,  NISHIGUCHI Shuhei (Hyogo Coll. Medicine, Kakogawa) ,  MORIWAKI Hisataka (Study Group on New Liver Cancer Therapies) ,  MORIWAKI Hisataka (Gifu Univ. Graduate School of Medicine, Gifu) ,  YAMAMOTO Kazuhide (Study Group on New Liver Cancer Therapies) ,  YAMAMOTO Kazuhide (Okayama Univ. Graduate School of Medicine, Okayama) ,  SATA Michio (Study Group on New Liver Cancer Therapies) ,  SATA Michio (Kurume Univ. School of Medicine, Kurume) ,  OBI Shuntaro (Study Group on New Liver Cancer Therapies) ,  OBI Shuntaro (Kyoundo Hospital, Tokyo)
Material： Hepatology Research  (Hepatol Res)
Volume： 42  Issue： 6  Page： 523-542  Publication year： Jun. 2012 
JST Material Number： W1284A  ISSN： 1386-6346  Document type： Article
Article type： 解説  Country of issue： Australia (AUS)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： Child-Pugh classification ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=12A1121945&from=J-GLOBAL&jstjournalNo=W1284A") }}

JST classification (2)： Tumors(=neoplasms)of digestive system  (GH04000D) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (1)： Sorafenib

Reference (35)：

• LLOVET, JM. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008, 359, 378-390
• CHENG, AL. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10, 25-34
• KUDO, M. Treatment Strategy for HCC Cases Refractory for TACE. Hepatocelluar Carcinoma Practice Manual. 2010, 118-121
• Bayer Heathcare. Nexavar^【○!R】 adverse reaction reports liver injury and interstitial pulmonary disease. 2010
• ABOU-ALFA, GK. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006, 24, 4293-4300

Terms in the title (4)： 肝細胞癌 ,  治療 ,  抗癌剤 ,  ガイドライン